What is Leerink Partnrs’ Forecast for KALV Q4 Earnings?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Stock analysts at Leerink Partnrs issued their Q4 2025 earnings per share (EPS) estimates for shares of KalVista Pharmaceuticals in a note issued to investors on Tuesday, March 25th. Leerink Partnrs analyst J. Schwartz anticipates that the specialty pharmaceutical company will post earnings of ($0.77) per share for the quarter. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share. Leerink Partnrs also issued estimates for KalVista Pharmaceuticals’ Q1 2026 earnings at ($0.72) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.41) EPS and FY2027 earnings at ($1.27) EPS.

Several other analysts also recently commented on KALV. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Citizens Jmp upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. Needham & Company LLC reiterated a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Wednesday. JMP Securities began coverage on KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an “outperform” rating and a $19.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $24.83.

KalVista Pharmaceuticals Trading Up 2.2 %

NASDAQ KALV opened at $12.34 on Friday. KalVista Pharmaceuticals has a 12 month low of $7.30 and a 12 month high of $15.50. The stock has a market cap of $613.50 million, a price-to-earnings ratio of -3.39 and a beta of 0.76. The company’s 50 day moving average is $10.49 and its two-hundred day moving average is $10.26.

Institutional Trading of KalVista Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Aquatic Capital Management LLC purchased a new position in KalVista Pharmaceuticals in the fourth quarter worth about $44,000. Tower Research Capital LLC TRC lifted its stake in shares of KalVista Pharmaceuticals by 666.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 5,502 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of KalVista Pharmaceuticals by 22.5% in the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 1,494 shares during the period. Martin Worley Group bought a new position in shares of KalVista Pharmaceuticals during the 4th quarter valued at approximately $86,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in KalVista Pharmaceuticals by 24.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after buying an additional 2,043 shares during the period.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 6,669 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $11.97, for a total transaction of $79,827.93. Following the completion of the transaction, the chief executive officer now directly owns 287,811 shares in the company, valued at approximately $3,445,097.67. This represents a 2.26 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Paul K. Audhya sold 3,125 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total transaction of $30,687.50. Following the completion of the sale, the insider now owns 100,334 shares in the company, valued at $985,279.88. This represents a 3.02 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders bought 236,055 shares of company stock worth $2,162,146 and sold 17,292 shares worth $184,625. 10.50% of the stock is currently owned by company insiders.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).